RT Journal Article
SR Electronic
T1 Prognostic value of flow-mediated dilation and computed tomography angiography findings for determining cardiovascular risk in patients with subclinical atherosclerosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.24.23289070
DO 10.1101/2023.04.24.23289070
A1 Kawai, Hideki
A1 Sarai, Masayoshi
A1 Sugimoto, Kunihiko
A1 Motoyama, Sadako
A1 Sato, Yoshihiro
A1 Nagahara, Yasuomi
A1 Miyajima, Keiichi
A1 Matsuyama, Takahiro
A1 Takahashi, Hiroshi
A1 Yamada, Akira
A1 Naruse, Hiroyuki
A1 Toyama, Hiroshi
A1 Ozaki, Yukio
A1 Izawa, Hideo
YR 2023
UL http://medrxiv.org/content/early/2023/05/04/2023.04.24.23289070.abstract
AB Background Flow-mediated dilation (FMD) tests endothelial function, and computed tomography angiography (CTA) estimates the extent of coronary atherosclerosis and plaque vulnerability. This study aimed to examine the prognostic value of combining FMD and CTA in patients with no history of atherosclerotic disease.Methods The study retrospectively examined patients who underwent CTA and FMD within 3 months between 2012 and 2020. Patients with a history of cardio-cerebrovascular disease or significant stenoses on CTA were excluded. The study endpoint was defined as major cardiac and cerebrovascular events (MACCE): a composite of cardio-cerebrovascular death, acute coronary syndrome, fatal arrhythmia, ischaemic and haemorrhagic stroke, and late revascularisation of the coronary or carotid arteries 6 months after CTA. Finally, the patients were stratified into four groups based on the following factors: FMD <6.0%, per cent atheroma volume (PAV) ≥21.0%, and the presence of high-risk plaques (HRPs).Results During a mean follow-up of 4.7 years, MACCE occurred in 19 of 154 patients (mean age: 61.0±12.9 years, 89 males). FMD, PAV, and HRPs were independent predictors of MACCE after adjusting for age, sex, and hypertension. Compared with the patients with 0 points, hazard ratios of those with 1, 2, and 3 points were 2.76 (P=0.322), 9.89 (P=0.004), and 28.43 (P<0.001), respectively. Adding FMD, PAV, and HRPs to the baseline model, including age, sex, and hypertension, improved the C-index (0.712–0.831, P=0.023).Conclusions Although FMD and CTA findings are useful for predicting cardiovascular events, their combination synergises their prognostic abilities.Competing Interest StatementHiroshi Toyama has received research grants from Canon Medical Systems. Hideo Izawa has received grant support through his institution from Bayer, Daiichi-Sankyo, Dainihon-Sumitomo, Kowa, Ono, Otsuka, Takeda, and Fuji Film Toyama Kagaku, as well as honoraria for lectures from Boehringer Ingelheim, Daiichi-Sankyo, Novartis, and Otsuka Corporation. The remaining authors have nothing to disclose.Clinical TrialThis is a retrospective study.Funding StatementNothingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board (IRB) of Fujita Health University, under the approval number "HM20-161". The IRB reviewed and approved the research protocol, ensuring that the study adheres to ethical guidelines and regulations.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableAll data generated or analyzed during this study are included in this published article and its supplementary information files. The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.ACSacute coronary syndromeAUCarea under the ROC curveCACScoronary artery calcium scoreCADcoronary artery diseaseCIconfidence intervalCTcomputed tomographyCTAcomputed tomography angiographyFMDflow-mediated dilationHRhazard ratioHRPhigh-risk plaqueHUHounsfield unitIDIintegrated discrimination improvementIVUSintravascular ultrasoundNRInet reclassification improvementMACCEmajor cardiac and cerebrovascular eventsPAVper cent atheroma volumeROCreceiver operating characteristic